Kidney Cancer Journal and
Kidney Cancer Journal International
are the Official Journals of the Kidney Cancer Association
Kidney Cancer Journal Fact Sheet
• Kidney Cancer Journal is the Official Journal of the Kidney Cancer Association
• Kidney Cancer Journal is the only peer-reviewed medical journal and most comprehensive
Xsource of scientific information focusing exclusively on renal cell carcinoma
• Robert A. Figlin, MD, Editor-in-Chief. Principal investigator on numerous kidney cancer
Xclinical trials. Professor and Department Chair, Medical Oncology and Therapeutic Research,
XCity of Hope National Medical Center, Duarte, California
• Published quarterly since December, 2003
• Distributed as a complimentary professional service to 25,512 physicians, including all
Xmedical oncologists, hematologist-oncologists and urologists in U.S.
• Utilizes a Medical Advisory Board and Editorial Advisory Board of more than 30 physicians
Xwho are leading investigators in this field
• CME credit in each issue offered through City of Hope National Medical Center, Duarte,
XCalifornia
• Archives available through the KCA’s website http://www.kidneycancerjournal.org
• Special Reports and supplements covering ASCO and highlights from the annual
XInternational Kidney Cancer Association Meeting
• Program pricing available upon request
• Frank Iorio, Director of Business Development
Kidney Cancer Journal International Fact Sheet
• Kidney Cancer Journal International provides physicians throughout Europe, Japan and
XSouth America with the only journal focused on worldwide developments in renal cancer, with
Xspecial emphasis on trends and translational research in the EU. It is editorially driven by EU
Xphysicians and concentrate on new treatment standards affecting quality care in these
Xcountries by providing more of a global perspective.
• Launched with the Spring 2007 issue
• Kidney Cancer Journal International is the Official Journal of the Kidney Cancer Association.
• Distributed as a complementary professional service to 15,000 physicians, including all
Xmedical oncologists, urologists, urologic oncologists in EU, Japan and South America
• Mailing list is compiled from ESMO lists, ASCO international list and additional mail house lists
• Timothy Eisen, MD PhD, UK, Bernard Escudier, MD, France, Editors-in-Chief
• Robert A. Figlin, MD, Senior Editor
• Medical Advisory Board, including Martin Gore, MD, PhD, Sylvie Negrier, MD,
XJacques Patard, MD, Cora Sternberg, MD, Peter F.A. Mulders, MD
• Editorial Advisory Board including 12 leading principal investigators, including
X4 physicians from U.S.
• Published quarterly
• Printing and Distribution from United Kingdom
• Program pricing available upon request
• Frank Iorio, Director of Business Development
The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals. We fund, promote, and collaborate with the National Cancer Institute (NCI), American Society for Clinical Oncology (ASCO), American Urologic Association (AUA), and other institutions on research projects. They educate families and physicians, and serve as an advocate on behalf of patients at the state and federal levels.
The Kidney Cancer Association was founded in 1990 by a small group of patients, including Eugene P. Schonfeld, Ph.D., and medical doctors in Chicago, Illinois. It is a nonprofit charity incorporated in the State of Illinois. It has also been designated as a tax exempt organization under Section 501(c)(3) of the U.S. Internal Revenue Service code. Donations to the Association are tax deductible.
The Kidney Cancer Association is a member of, and is certified by, the National Health Council as an organization in full compliance with the Standards of Excellence for voluntary health agencies.
The Kidney Cancer Association is developing a global presence and is creating websites in several languages, including Chinese, Japanese, Spanish, German, French, Italian and other languages. New patient support groups are planned for the European Union, Asia and Australia in 2007.
Kidney Cancer Journal
Official Journal of the Kidney Cancer Association
2009 ADVERTISING RATE CARD
| |
1X |
4X |
8X |
12X |
16X |
24X |
Full page (B&W) |
5,525 |
5,395 |
5,310 |
5,195 |
5,085 |
4,980 |
1/2 page (B&W) |
4,425 |
4,310 |
4,250 |
4,155 |
4,075 |
3,980 |
1/4 page (B&W) |
2,765 |
2,695 |
2,655 |
2,600 |
2,550 |
2,485 |
Color Charges
2 Color $750
4 Color $1,650
Total Circulation: 25,512
Kidney Cancer Journal International
Official Journal of the Kidney Cancer Association
2009 ADVERTISING RATE CARD
| |
1X |
4X |
8X |
12X |
16X |
24X |
Full page (B&W) |
3,375 |
3,290 |
3,240 |
3,175 |
3,105 |
3,045 |
1/2 page (B&W) |
2,705 |
2,635 |
2,590 |
2,540 |
2,485 |
2,435 |
1/4 page (B&W) |
1,695 |
1,645 |
1.625 |
1,595 |
1,560 |
1,520 |
Color Charges
2 Color $450
4 Color $1,000
Total Circulation: 15,000
2009 Issue and Closing Date - Kidney Cancer Journal
WINTER Issue: February 20 |
SPACE Closing: January 23 |
MATERIALS Due: January 30 |
SPRING Issue: May 22 |
SPACE Closing: April 24 |
MATERIALS Due: May 1 |
SUMMER Issue: August 21 |
SUMMER Issue: August 21 |
MATERIALS Due: July 31 |
AUTUMN Issue: November 20 |
SPACE Closing: October 23 |
MATERIALS Due: October 30 |
2009 Issue and Closing Date - Kidney Cancer Journal International
WINTER Issue: February 20 |
SPACE Closing: January 23 |
MATERIALS Due: January 30 |
SPRING Issue: May 22 |
SPACE Closing: April 24 |
MATERIALS Due: May 1 |
SUMMER Issue: August 21 |
SPACE Closing: July 24 |
MATERIALS Due: July 31 |
AUTUMN Issue: November 20 |
SPACE Closing: October 23 |
MATERIALS Due: October 30 |
Dates subject to change
Communications Interactions
Kidney Cancer Journal and
Kidney Cancer Journal International
Communications Interactions
Connect with Professionals
• Clinical Trial Recruitment
• CME
• Live Events: Symposia, Grand Rounds
• Podcasts
• Product Advertising
• Customized Educational Programs
Communications Interactions
Connect with Patients
• Clinical Updates
• News from Industry
• Side-effects Awareness & Management
• Compliance
• Concurrent Condition Awareness & Management
• Care-giver Support
• Newsletters
Common Issues Associated
with RCC Therapy
• Hypertension
• Pain Management
• Dehydration
• Nutrition
• Fatigue
• Sleep Disorders
• Depression
Communications Opportunities
Print and Website Advertising
• Reprints
• Sponsored Subscriptions
• Newsletters
• Supplements
• CME Grants
• Live Events
• Patient Education Programs
• Customized Programs
Current and Past Supporters
• Sutent (Pfizer)
• Nexavar (Bayer/Onyx)
• A.R.I.S.E.R. (Wilex)
• R.E.C.O.R.D. - 1 (Novartis)
• Proleukin (Novartis/Chiron)
• Zometa (Novartis)
• TargetmTOR (Novartis)
• Clinical Trial Recruitment (GSK)
• T.A.R.G.E.T.S. (Bayer/Onyx)
• Oncophage (Antigenics)
• ASCO (Bayer/Onyx)
• Temsirolimus (Wyeth)
• CME Activity (Wyeth)
• Genentech (Corporate)
• Torisel (Wyeth)
Kidney Cancer Journal and
Kidney Cancer Journal International
The Team
• Robert A. Figlin, MD - Editor-in-Chief
• Stu Chapman - Executive Editor
• Jenny Chapman - Assoc. Dir, Editorial Services
• Frank Iorio - Director of Business Development
• Heidi Green - Associate Editor
• Gloria Catalano - Production Director
• Michael McClain - Design Director
